What is the treatment for herpetic whitlow?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Herpetic Whitlow

Initiate oral antiviral therapy immediately upon diagnosis with acyclovir 400 mg three times daily, valacyclovir 1 g twice daily, or famciclovir 250 mg three times daily for 7-10 days. 1

First-Line Treatment Approach

The CDC recommends oral antiviral therapy as the cornerstone of treatment, which should be started as soon as possible after diagnosis 1. The three equivalent first-line options are:

  • Acyclovir 400 mg orally three times daily for 7-10 days 1
  • Valacyclovir 1 g orally twice daily for 7-10 days 1
  • Famciclovir 250 mg orally three times daily for 7-10 days 1

Treatment duration may be extended beyond 10 days if healing remains incomplete 1. While herpetic whitlow can be self-limiting and resolve without intervention in approximately three weeks, antiviral therapy significantly accelerates healing and reduces viral shedding 2, 3.

Critical Treatment Considerations

Avoid topical antiviral therapy—it is substantially less effective than systemic treatment and is not recommended. 1, 4 This is a common pitfall, as topical acyclovir has minimal efficacy compared to oral regimens 4.

Do not perform surgical drainage or incision. 5 Herpetic whitlow is frequently misdiagnosed as bacterial paronychia or felon, leading to unnecessary surgical intervention that prolongs morbidity and increases complications 6, 5.

Special Populations and Severe Cases

Immunocompromised Patients

Higher antiviral doses are required for immunocompromised patients 1:

  • Acyclovir 400 mg orally three to five times daily until clinical resolution 1
  • For severe cases: Intravenous acyclovir 5 mg/kg every 8 hours 1
  • If lesions persist despite acyclovir treatment, suspect resistance and consider foscarnet 40 mg/kg IV every 8 hours until clinical resolution 1, 7

A case report documented successful treatment of acyclovir-resistant herpetic whitlow in an HIV-positive patient using foscarnet after multiple standard antiviral regimens failed 7.

Recurrent Episodes

For patients experiencing recurrent herpetic whitlow 1:

Episodic therapy (start at first sign of prodrome):

  • Acyclovir 400 mg orally three times daily for 5 days 1
  • Valacyclovir 500 mg orally twice daily for 5 days 1

Suppressive therapy (for frequent recurrences):

  • Acyclovir 400 mg orally twice daily 1
  • Valacyclovir 250 mg orally twice daily, or 500-1000 mg once daily 1

After 1 year of continuous suppressive therapy, consider discontinuation to reassess recurrence frequency 1.

Patient Management Essentials

Instruct patients to avoid contact with lesions to prevent autoinoculation or transmission to others. 1 This is particularly important for healthcare workers, as herpetic whitlow is an occupational hazard 3, 6.

Monitor for complete lesion resolution 1. If symptoms worsen despite treatment, consider secondary bacterial infection (which can coexist with viral infection) or antiviral resistance, and adjust treatment accordingly 1, 6.

References

Guideline

Treatment Protocol for Herpetic Whitlow

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of mucocutaneous herpes simplex infections with acyclovir.

Journal of the American Academy of Dermatology, 1988

Guideline

Treatment for Recurrent Genital Herpes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Herpetic whitlow.

The Medical journal of Australia, 1979

Research

An Unusual Pediatric Manifestation of the Herpes Simplex Virus.

Journal of the American Podiatric Medical Association, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.